Overall, prasugrel may be superior to the approved dose of the older drug, clopidogrel (Plavix), in many cases. But more doctors have been using an initial, higher-than-standard dose of ...

In TRILOGY ACS, the drug failed to surpass clopidogrel in patients who do not undergo revascularization for acute coronary syndromes. Prasugrel sales are flagging, despite the robust marketing ...

The new P2Y 12 antagonists, prasugrel and ticagrelor, are characterized by more potent antiplatelet effects and reduce recurrent ischemic event rates compared with clopidogrel among acute coronary ...